Reported about 24 hours ago
Eli Lilly's stock has had a volatile month, dropping 22% from its peak primarily due to disappointing earnings in October and competition in the weight loss medication market. Despite concerns around new competitors and Amazon's entrance into healthcare, analysts argue that Eli Lilly remains a strong player with significant opportunities, especially after receiving FDA approvals for new medications. The current dip is seen as a promising buying opportunity for investors looking to capitalize on the company's position in the healthcare sector.
Source: YAHOO